Ranking · Summer 2020 · Healthcare · Therapeutics

Nephrogen

Curative genetic medicines for kidney diseases

5.9%

odds of being acquired in the next two years

0.9× the average (6.8%)

#2707 of 4,339 active YC companies · top 63%

Team of 5 · New York City, NY, USA

Raises the odds

↑ team of 3–5

↑ based in United States of America

↑ rewrote its description in the last six months

↑ based in America / Canada

Lowers the odds

↓ industry: Healthcare

↓ tag: Biotech

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Nephrogen's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

nephrogenbiotech.com YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub